Novel tricyclic aromatic heterocyclic compounds, and their preparation methods, pharmaceutical compositions and applications

Abstract

The present invention provides novel tricyclic aromatic heterocyclic compounds, as well as their preparation methods, pharmaceutical compositions and applications, specifically, the present invention provides a compound as shown in the following formula I, or an optical isomer, hydrate, solvate, or pharmaceutically acceptable salt thereof, wherein the definitions of each group are as described in the specification. The compound of formula I can be used to treat diseases associated with the PD-1 / PD-L1 signaling pathway. [Formula 1] JPEG2023526548000090.jpg60152

Description

[Technical Field]

[0001] The present invention relates to the field of small molecule drugs, and in particular, the present invention provides small molecule compounds that can be used to treat diseases associated with the PD-1 / PD-L1 signaling pathway. [Background technology]

[0002] The immune system plays a crucial role in the control and treatment of many diseases, including various cancers and diseases caused by viruses. However, cancer cells can rapidly proliferate by evading or inhibiting the immune system through several pathways. One of these pathways is by altering the activating and inhibitory molecules expressed on immune cells. Blockade of inhibitory immune checkpoints, such as PD-1, has proven to be a highly effective method for inhibiting cancer cells.

[0003] PD-1, also known as CD279, is a programmed cell death protein-1 (PD-1) expressed primarily on activated T and B cells. Its function is to inhibit cell activation, a normal self-stabilizing mechanism of the immune system. PD-1 acts as a defense against autoimmune diseases, as excessive T and B cell activation can lead to autoimmune diseases. PD-1 is a type I transmembrane glycoprotein consisting of 268 amino acids. Its structure primarily consists of an outer immunoglobulin variable region, a hydrophobic transmembrane region, and an intracellular region. The intracellular region contains two phosphorylation sites located in the immunoreceptor tyrosine-based inhibitory motif and immunoreceptor tyrosine-based transducing motif, respectively, demonstrating that PD-1 can reversely regulate T cell receptor-mediated signals. PD-1 has two ligands, PD-L1 and PD-L2, which have different expression patterns. PD-L1 is upregulated on a variety of tumor cells, and it binds to PD-1 on T cells, inhibiting T cell proliferation and activation, rendering T cells in an inactivated state and ultimately inducing immune escape.

[0004] PD-1 / PD-L1 plays a role in inverse immune regulation. After PD-1 binds to PD-L1, it can induce tyrosine polyphosphorylation at the T cell immunoreceptor tyrosine transduction motif domain, and the phosphorylated tyrosine can bind to the phosphatases protein tyrosinase 2 and protein tyrosinase 1. This inhibits the activation of extracellular signal-regulated kinase (EPK) and phosphoinositide 3-kinase (PI3K) and serine-threonine protein kinase (Akt), thereby inhibiting T lymphocyte proliferation and related cytokine secretion. PD-1 / PD-L1 signaling inhibits T cell activation and proliferation while also inducing the secretion of cytokines such as interleukin 2, interferon-γ, and IL-10. Furthermore, PD-1 / PD-L1 signaling has a similar immune function on B cells. After PD-1 binds to the B cell antigen receptor, the PD-1 cytoplasmic region interacts with tyrosinase, which contains a protein tyrosinase 2-binding site, thereby inhibiting B cell activation.

[0005] PD-1 / PD-L1-based immunotherapy is a new generation of immunotherapy that has attracted much attention. In recent years, a series of surprising research results have confirmed that PD-1 / PD-L1 inhibitors have potent antitumor activity against various tumors. Currently available PD-1 / PD-L1 antibody inhibitors include BMS's Ninolumab, Merck's Lambrolizumab, and Roche's Atezolizumab. In addition, there are more PD-1 / PD-L1 antibody inhibitors under investigation, including CureTech's Pidilizumab, GSK's AMP-224, and AstraZeneca's MEDI-4736.

[0006] Tumor immunotherapy is considered to be a new generation revolution in cancer treatment following targeted therapy, but the PD-1 monoclonal antibody drugs currently on the market and under investigation have their own drawbacks, including the fact that they can only be administered by injection, cannot be administered orally, are unstable in the body, are easily degraded by proteases, are prone to immune cross-reactivity, are relatively difficult to purify, and have high production costs. Therefore, small molecule inhibitors of the PD-1 / PD-L1 interaction are a better option for tumor immunotherapy. In summary, there is an urgent need in the art to develop novel small molecule modulators of the PD-1 / PD-L1 interaction. Summary of the Invention [Problem to be solved by the invention]

[0007] It is an object of the present invention to provide novel small molecule modulators of the PD-1 / PD-L1 interaction. [Means for solving the problem]

[0008] A first aspect of the present invention provides a compound as shown in Formula I below, or an optical isomer, hydrate, solvate, or pharmaceutically acceptable salt thereof: [ka] where n is 0, 1, 2, or 3; m, p, q, and t are each independently selected from 0, 1, 2, 3, or 4; X1, X2, X3, X4, X5 and X6 are each independently selected from the group consisting of N, O, S, SO, SO2, C(R)2 and NR; Y1, Y2, Y3, Y4, Y5 and Y6 are each independently selected from the group consisting of N, CH and C; [ka] is a substituted or unsubstituted C1-C 15an aryl group, or a substituted or unsubstituted 4- to 12-membered (preferably 5- to 7-membered) heteroaryl group having 1 to 4 heteroatoms; a substituted or unsubstituted 4- to 12-membered heterocyclic group; a substituted or unsubstituted 4- to 12-membered C5-C 12 cycloalkyl groups, [ka] is a substituted or unsubstituted C1-C 15 an arylene group, or a substituted or unsubstituted 4- to 12-membered (preferably 5- to 7-membered) heteroarylene group having 1 to 4 heteroatoms; a substituted or unsubstituted 4- to 12-membered heterocyclylene group; a substituted or unsubstituted 4- to 12-membered C5-C 12 cycloalkylene groups; R, R1, R2, R3, R4 and R5 each independently represent H, -CN, a trifluoromethyl group, a sulfonylamino group, a nitro group, a hydroxyl group, a halogen, -S-R8, -S(O)-R8, -S(O)2-R8, a substituted or unsubstituted C1-C 10 alkyl group, substituted or unsubstituted C2-C6 alkenyl group, substituted or unsubstituted C2-C6 alkynyl group, substituted or unsubstituted C1-C6 alkoxy group, substituted or unsubstituted C3-C8 cycloalkyl group, oxo (i.e., =O), =NRf, -CN, hydroxyl group, NRdRe (e.g., amino group), substituted or unsubstituted C1-C6 amine group, substituted or unsubstituted -(C1-C6 alkylene)-NH-(C1-C6 alkylene), carboxyl group, substituted or unsubstituted C6-C 10 aryl groups, substituted or unsubstituted 5- to 12-membered heteroaryl groups having 1 to 3 heteroatoms, substituted or unsubstituted 3- to 12-membered heterocyclic groups having 1 to 4 heteroatoms, substituted or unsubstituted [ka] , substituted or unsubstituted [ka] , or -(L1a)r-(L2a)s-(L3a)s-, -C 0-8-O-R8, -C 0-8 -C(O)OR8, -C 0-8 -OC(O)OR8, -C 0-8 -NR8R9, -C 0-8 -N(R8)C(O)R9, -C 0-8 -C(O)NR8R9; or or R1 and R2 together with the ring atoms to which they are attached form a 5-, 6- or 7-membered carbocyclic ring or a 5-, 6- or 7-membered heterocyclic ring, wherein said heterocyclic ring contains 1, 2 or 3 selected from N, S or O, and said carbocyclic or heterocyclic ring may be an aromatic ring bonded to ring B, or a non-aromatic or saturated ring containing an unsaturated bond; R8 and R9 are each independently H, a hydroxyl group, a substituted or unsubstituted C1-C 10 alkyl group, substituted or unsubstituted C2-C6 alkenyl group, substituted or unsubstituted C2-C6 alkynyl group, substituted or unsubstituted C1-C6 alkoxy group, substituted or unsubstituted C3-C8 cycloalkyl group, oxo (i.e., =O), =NRf, -CN, hydroxyl group, NRdRe (e.g., amino group), substituted or unsubstituted C1-C6 amine group, substituted or unsubstituted -(C1-C6 alkylene)-NH-(C1-C6 alkylene), carboxyl group, substituted or unsubstituted C6-C 10 aryl groups, substituted or unsubstituted 5- to 12-membered heteroaryl groups having 1 to 3 heteroatoms, substituted or unsubstituted 3- to 12-membered heterocyclic groups having 1 to 4 heteroatoms, substituted or unsubstituted [ka] , substituted or unsubstituted [ka] or -(L1a)r-(L2a)s-(L3a)s-; each L1a is independently a group selected from the group consisting of a chemical bond, a substituted or unsubstituted C1-C7 alkylene group, a substituted or unsubstituted C2-C4 alkenylene group, a substituted or unsubstituted C2-C4 alkynylene group, -S-, -O-, substituted or unsubstituted -NH-, -S(O)-, or -S(O)2-; L2a is a substituted or unsubstituted C6-C 12 an arylene group, a substituted or unsubstituted 5- to 12-membered heteroarylene group having 1 to 3 heteroatoms, a substituted or unsubstituted C3-C8 cycloalkylene group, and a substituted or unsubstituted 5- to 10-membered heterocyclylene group having 1 to 3 heteroatoms; L3a is a substituted or unsubstituted C1-C 10 Alkyl groups, C1-C 10 selected from the group consisting of an aryl group, -CN, a hydroxyl group, an amino group, a carboxyl group, -CO-NH-SO2-Rg, -NH-SO2-Rg, and -SO2-NH-CO-Rg; r is 1, 2, 3, 4, 5, 6, s is 0, 1, and 2, respectively. Rd, Re and Rg are each independently H, a substituted or unsubstituted C1-C6 alkyl group, a substituted or unsubstituted C3-C 10 Cycloalkyl groups, substituted or unsubstituted C6-C 10 aryl groups, or Rd and Re together form a substituted or unsubstituted 5-10 membered heterocyclic group having 1-3 heteroatoms selected from N, S and O; wherein Rf is H, a substituted or unsubstituted C1-C6 alkyl group, a substituted or unsubstituted C6-C 10 Aryl groups, substituted or unsubstituted C6-C 10 Heteroaryl group, cyano group, -C(=O)-NRdRe, -C(=O)-substituted or unsubstituted C1-C6 alkoxy group, -C(=O)-substituted or unsubstituted C1-C6 alkyl group, -C(=O)-substituted or unsubstituted C3-C 10a cycloalkyl group, a -C(=O)-substituted or unsubstituted C2-C6 alkenyl group, a -C(=O)-substituted or unsubstituted C2-C6 alkynyl group; Unless otherwise specified, the term "substituted" refers to, for example, halogen, including but not limited to, -F, Cl, Br, -CH2Cl, -CHCl2, -CCl3, -CH2F, -CHF2, -CF3, oxo, -CN, hydroxyl group, amino group, C1-C6 alkylamino group, carboxyl group, -NHAc, or C1-C6 alkyl group, C1-C6 alkoxy group, C6-C 10 Aryl groups, C3-C8 cycloalkyl groups, halogenated C6-C 10 aryl groups, 5-10 membered heteroaryl groups having 1-3 heteroatoms selected from N, S, and O, and 5-10 membered heterocyclic groups having 1-3 heteroatoms selected from N, S, and O (which are unsubstituted or substituted with one or more substituents selected from the group consisting of halogens, hydroxyl groups, carboxyl groups, cyano groups, C1-C6 alkoxy groups, and C1-C6 alkylamino groups); In each of the above formulas, any of the heteroatoms is selected from the group consisting of B, P, N, S and O.

[0009] In another preferred example, R4 is [ka] wherein Rb, Rc, and Rd are each independently selected from the group consisting of H and a substituted or unsubstituted C1-C8 alkyl group, or Rb and Rc, together with the adjacent N atom, form a substituted or unsubstituted 4- to 10-membered heterocyclic group having 1 to 3 heteroatoms selected from N, S, and O.

[0010] In another preferred embodiment, [ka] teeth, [ka] wherein the attachment point of said ring can be N or C.

[0011] In another preferred example, R3 is selected from the group consisting of a methyl group, -F, Cl, Br, -CH2Cl, -CHCl2, -CCL3, -CH2F, -CHF2, -CF3, -CN, a hydroxyl group, and an amino group.

[0012] In another preferred embodiment, [ka] teeth, [ka] and wherein R1 and R2 are each independently H, halogen, substituted or unsubstituted C1-C 10 The alkyl group is selected from the group consisting of:

[0013] In another preferred embodiment, [ka] is a structure selected from the group consisting of: [ka] [ka]

[0014] In another preferred embodiment, [ka] is the structure shown below. [ka]

[0015] In another preferred embodiment, [ka] is a structure selected from the group consisting of: [ka]

[0016] In another preferred embodiment, the compound is selected from the following compounds: [ka] [ka] [ka] [ka] [ka] [ka]

[0017] A second aspect of the present invention provides a process for preparing a compound of formula I according to the first aspect of the present invention, said process comprising steps selected from those shown in synthetic scheme 1 or 2, Synthesis method 1: [ka] (a) Using intermediates 1 and 2 as raw materials, the target product I-1 is obtained by Sonogashira coupling reaction catalyzed by a palladium catalyst; Preferably, the process for preparing intermediate 1 is as follows: [ka] Compound 1-1 is used as a raw material, and intermediate 1-2 is formed by coupling reaction under the conditions of palladium catalyst and ligand; (b) Using 1-2 as a raw material, condensation reaction with primary and secondary amines under Lewis acid catalysis, followed by further reduction with a suitable reducing agent to form intermediate 1-3, or direct reductive amination reaction in the presence of a reducing agent to form intermediate 1-3; (c) Using 1-3 as a raw material, a halogenation reaction is carried out under the catalysis of a Lewis acid to obtain intermediate 1; Synthesis method 2: [ka] (a) Using compound 3-1 as a raw material, a nitrating agent reaction (e.g., concentrated sulfuric acid / NaNO3, concentrated sulfuric acid / fuming nitric acid, etc.) is carried out to form intermediate 3-2; (b) 3-2 is used as a raw material and reduced under reducing conditions (Pd-C / H, zinc powder / ammonium chloride, iron powder / acetic acid, etc.) to form intermediate 3-3; (c) Using 3-3 and 3-4 as raw materials, a condensation reaction is carried out under the conditions of a condensing agent, and an appropriate oxidizing agent (e.g., DDQ, etc.) is added to carry out an oxidation reaction to obtain intermediate 3-5; (d) 3-5 and 3-6 are used as raw materials to undergo a coupling reaction under catalytic and ligand conditions to form intermediate I-2.

[0018] A third aspect of the present invention provides a pharmaceutical composition comprising: (1) a compound according to the first aspect of the present invention, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof; and (2) a pharmaceutically acceptable carrier.

[0019] A fourth aspect of the present invention provides use of a compound according to the first aspect of the present invention, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to the third aspect of the present invention, for use in the preparation of a pharmaceutical composition for the prevention and / or treatment of a disease associated with the activity or expression level of PD-1 / PD-L1.

[0020] A fifth aspect of the present invention provides a PD-1 / PD-L1 modulator, which comprises a compound according to the first aspect of the present invention, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof.

[0021] In another preferred embodiment, the pharmaceutical composition is used to treat a disease selected from the group consisting of cancer, infectious diseases, and autoimmune diseases. In another preferred example, the cancer is selected from the group consisting of pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, kidney cancer, hepatocellular carcinoma, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, melanoma, neuroendocrine cancer, central nervous system cancer, brain cancer, bone cancer, soft tissue sarcoma, non-small cell lung cancer, small cell lung cancer or colon cancer, skin cancer, lung cancer, urological tumors, blood tumors, glioma, digestive system tumors, reproductive system tumors, lymphoma, nervous system tumors, brain tumors, and head and neck cancer.

[0022] In another preferred example, the cancer is selected from the group consisting of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), myelodysplastic syndrome (MDS), myeloproliferative disorder (MPD), chronic myelogenous leukemia (CML), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma, Waldestromm's macroglobulinemia (WM), T-cell lymphoma, B-cell lymphoma, or diffuse large B-cell lymphoma (DLBCL).

[0023] In another preferred embodiment, the infectious disease is selected from bacterial infections and viral infections. In another preferred embodiment, the autoimmune disease is selected from an organ-specific autoimmune disease and a systemic autoimmune disease. In another preferred embodiment, the organ-specific autoimmune disease includes chronic lymphocytic thyroiditis, hyperthyroidism, insulin-dependent diabetes mellitus, myasthenia gravis, ulcerative colitis, pernicious anemia with chronic atrophic gastritis, pulmonary hemorrhagic nephritic syndrome, primary biliary cirrhosis, multiple encephalomyelitis, and acute idiopathic polyneuropathy.

[0024] In another preferred embodiment, the systemic autoimmune disease includes rheumatoid arthritis, systemic lupus erythematosus, systemic vasculitis, scleroderma, pemphigus, dermatomyositis, mixed connective tissue disease, and autoimmune hemolytic anemia. In another preferred embodiment, the pharmaceutical composition is also used to improve T cell function in patients with chronic hepatitis B (CHB). In another preferred embodiment, the inhibitor further comprises at least one therapeutic agent selected from the group consisting of nivolumab, pembrolizumab, atezolizumab, or ipilimumab.

[0025] A sixth aspect of the present invention provides a method of modulating PD-1 / PD-L1 interaction in vivo, comprising contacting a compound according to the first aspect of the invention, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof, with PD-L1 protein. DETAILED DESCRIPTION OF THE INVENTION

[0026] As a result of extensive and thorough research, the present inventors have discovered an agent that modulates PD-1 / PD-L1 interaction with excellent regulatory effects, and have completed the present invention based on this discovery.

[0027] definition As used herein, the term "alkyl group" includes straight-chain or branched-chain alkyl groups. For example, a C1-C8 alkyl group refers to a straight-chain or branched-chain alkyl group having 1 to 8 carbon atoms, such as a methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, t-butyl group, etc.

[0028] As used herein, the term "alkenyl group" includes straight-chain and branched-chain alkenyl groups. For example, a C2-C6 alkenyl group refers to a straight-chain or branched-chain alkenyl group having from 2 to 6 carbon atoms, such as vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, or the like.

[0029] As used herein, the term "alkynyl group" includes straight-chain and branched-chain alkynyl groups. For example, a C2-C6 alkynyl group refers to a straight-chain or branched-chain alkynyl group having from 2 to 6 carbon atoms, such as an ethynyl group, a propynyl group, a butynyl group, or the like.

[0030] As used herein, "C3-C 10 The term "cycloalkyl group" refers to a cycloalkyl group having from 3 to 10 carbon atoms. It may be monocyclic, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or the like. It may be bicyclic, such as bridged or spirocyclic.

[0031] As used herein, the term "C1-C8 alkylamino group" refers to an amino group substituted with a C1-C8 alkyl group, which may be mono- or di-substituted, such as methylamino group, ethylamino group, propylamino group, isopropylamino group, butylamino group, isobutylamino group, t-butylamino group, dimethylamino group, diethylamino group, dipropylamino group, diisopropylamino group, dibutylamino group, diisobutylamino group, di-t-butylamino group, and the like.

[0032] As used herein, the term "C1-C8 alkoxy group" refers to a straight or branched chain alkoxy group having 1 to 8 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, and the like.

[0033] As used herein, the term "3- to 10-membered heterocycloalkyl group having 1 to 3 heteroatoms selected from the group consisting of N, S, and O" refers to a saturated or partially saturated cyclic group having 3 to 10 atoms, of which 1 to 3 heteroatoms are selected from the group consisting of N, S, and O. It may be a monocyclic or bicyclic group in the form of a bridged ring or a spirocyclic ring. Specific examples include oxetane, azetidine, tetrahydro-2H-pyranyl group, piperidinyl group, tetrahydrofuranyl group, morpholinyl group, and pyrrolidinyl group.

[0034] As used herein, "C6-C 10 The term "aryl group" refers to an aryl group having 6 to 10 carbon atoms, such as a phenyl group or a naphthyl group or similar group.

[0035] As used herein, the term "5- to 10-membered heteroaryl group having 1 to 3 heteroatoms selected from the group consisting of N, S, and O" refers to a cyclic aromatic group having 5 to 10 atoms, 1 to 3 of which are heteroatoms selected from the group consisting of N, S, and O. It may be a monocyclic or fused ring form. Specific examples include pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1,2,3)-triazolyl, (1,2,4)-triazolyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, etc.

[0036] Unless otherwise specified, the groups described in the present invention are "substituted or unsubstituted", and all groups in the present invention are substituted or unsubstituted, including halogen, nitrile, nitro, hydroxyl, amino, C1-C6 alkyl-amino, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, halogenated C1-C6 alkyl, halogenated C2-C6 alkenyl, halogenated C2-C6 alkynyl, halogenated C1-C6 alkoxy, allyl, benzyl, C6-C 12 It may be substituted by a substituent selected from the group consisting of an aryl group, a C1-C6 alkoxy-C1-C6 alkyl group, a C1-C6 alkoxy-carbonyl group, a phenoxycarbonyl group, a C2-C6 alkynyl-carbonyl group, a C2-C6 alkenyl-carbonyl group, a C3-C6 cycloalkyl-carbonyl group, a C1-C6 alkyl-sulfonyl group, and the like.

[0037] As used herein, "halogen" or "halogen atom" refers to F, Cl, Br, and I. More preferably, the halogen or halogen atom is selected from F, Cl, and Br. "Halogenated" refers to substitution with an atom selected from F, Cl, Br, and I.

[0038] Unless otherwise specified, the structural formulae depicted in the present invention are intended to include all isomeric forms (e.g., enantiomers, diastereomers, and geometric (or conformational) isomers), including asymmetric centers, such as the R and S configurations, and (Z) and (E) isomers of double bonds. Thus, all individual stereochemical isomers of the compounds of the present invention or mixtures of the enantiomers, diastereomers, or geometric (or conformational) isomers thereof are within the scope of the present invention.

[0039] As used herein, the term "tautomer" refers to structural isomers of different energies that can be interconverted across a low energy barrier. For example, proton tautomers (i.e., protonation) include interconversions via migration of a proton, such as 1H-indazole and 2H-indazole. Valence tautomers include interconversions via recombination of some bond electrons.

[0040] As used herein, the term "solvate" refers to a compound of the present invention that coordinates with solvent molecules to form a complex of a specific ratio. As used herein, the term "hydrate" refers to a complex formed when a compound of the present invention is coordinated with water.

[0041] Active ingredient As used herein, "compounds of the invention" refers to compounds shown in Formula I and further includes various crystalline forms, pharmaceutically acceptable salts, hydrates or solvates of the compounds of Formula I. Preferred compounds of the present invention include compounds 1 to 360 (including various R-configuration and / or S-configuration stereoisomers of each compound, and / or E- / Z-cis-trans isomers).

[0042] In another preferred example, the pharmaceutically acceptable salts include salts formed by combining with an inorganic acid, an organic acid, an alkali metal ion, an alkaline earth metal ion, or an organic base capable of providing a physiologically acceptable cation, and ammonium salts.

[0043] In another preferred example, the inorganic acid is selected from hydrochloric acid, hydrobromic acid, phosphoric acid, and sulfuric acid; the organic acid is selected from methanesulfonic acid, p-toluenesulfonic acid, trifluoroacetic acid, lysinic acid, maleic acid, tartaric acid, fumaric acid, citric acid, and lactic acid; the alkali metal ion is selected from lithium ion, sodium ion, and potassium ion; the alkaline earth metal ion is selected from calcium ion and magnesium ion; and the organic base capable of providing a physiologically acceptable cation is selected from methylamine, dimethylamine, trimethylamine, piperidine, morpholine, and tris(2-hydroxyethyl)amine.

[0044] All such salts within the scope of the present invention can be prepared by conventional methods. In the preparation process of the compound of general formula I and its solvates and salts, polycrystals or eutectics can occur under different crystallization conditions.

[0045] Preparation of Compounds of Formula I In order to prepare the compounds according to general formula I of the present invention, according to the structure of general formula I, the preparation of the compounds of general formula I in the present invention can be obtained by the following synthetic route: Formula 1: [ka] (a) Using intermediates 1 and 2 as starting materials, a coupling reaction catalyzed by a suitable palladium catalyst gives the target product I-1; An example of a method for preparing intermediate 1 is as follows: [ka] (a) compound 1-1 is used as a starting material (X is Cl, Br, or I) to form intermediate 1-2 by coupling reaction under suitable palladium catalyst and ligand conditions; (b) using 1-2 as a raw material, condensation reaction with primary and secondary amines under the catalysis of a suitable Lewis acid, followed by further reduction with a suitable reducing agent to form intermediate 1-3, or directly reductive amination reaction in the presence of a suitable reducing agent to form intermediate 1-3; (c) Using 1-3 as a raw material, a halogenation reaction is carried out under the catalysis of a suitable Lewis acid to obtain intermediate 1; Here, the preparation method of intermediate 2 is as follows: [ka] (a) Compounds 2-1 and 2-2 are used as raw materials and subjected to a coupling reaction (e.g., Suzuki, Buchwald, etc.) under appropriate palladium catalyst and ligand conditions to give intermediate 2-3; (b) Using 2-2 as a starting material, the silyl protecting group is removed using an appropriate reagent to give intermediate 2.

[0046] Furthermore, the starting materials and intermediates in the above reactions are readily available, and the reactions at each step can be easily synthesized according to published literature or by conventional methods in organic synthesis known to those skilled in the art.The compounds described in general formula I can exist in solvated or non-solvated forms, and different solvates may be obtained by crystallization using different solvents.

[0047] Formula 2: [ka] (a) Using compound 3-1 as a starting material, reacting it with a suitable nitrating agent (e.g., concentrated sulfuric acid / NaNO, concentrated sulfuric acid / fuming nitric acid, etc.) to form intermediate 3-2; (b) 3-2 is used as a raw material and reduced under appropriate reducing conditions (Pd-C / H, zinc powder / ammonium chloride, iron powder / acetic acid, etc.) to form intermediate 3-3; (c) 3-3 and 3-4 are used as raw materials, and are subjected to a condensation reaction under appropriate condensing agent conditions, followed by an oxidation reaction with an appropriate oxidizing agent (e.g., DDQ, etc.) to obtain intermediate 3-5; (d) using 3-5 and 2-1 as starting materials, under suitable catalyst and ligand conditions, a coupling reaction is carried out to form intermediate I-2; Furthermore, the starting materials and intermediates in the above reactions are readily available, and the reactions at each step can be easily synthesized according to published literature or by conventional methods in organic synthesis known to those skilled in the art.The compounds described in general formula I can exist in solvated or non-solvated forms, and different solvates may be obtained by crystallization using different solvents.

[0048] Pharmaceutical Compositions and Methods of Administration Since the compounds of the present invention have excellent activity in modulating PD-1 / PD-L1 interaction, the compounds of the present invention and their various crystalline forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates, as well as pharmaceutical compositions containing the compounds of the present invention as a main active ingredient, are used for preventing and / or treating (stabilizing, alleviating, or curing) diseases associated with PD-1 / PD-L1 interaction (e.g., cancer, infectious diseases, autoimmune diseases).

[0049] The pharmaceutical compositions of the present invention contain a compound of the present invention and a pharmaceutically acceptable excipient or carrier within a safe and effective amount. Here, "safe and effective amount" refers to an amount of the compound sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical composition contains 1 to 2000 mg of the compound / agent of the present invention, more preferably 10 to 200 mg of the compound / agent of the present invention. Preferably, the "single agent" is one capsule or tablet.

[0050] "Pharmaceutically acceptable carrier" refers to one or more compatible solid or liquid fillers or gel substances that must be of sufficient purity and sufficiently low toxicity to be suitable for human use. "Compatibility" refers to the ability of the components of the composition to blend with each other without significantly reducing the efficacy of the compounds of the present invention. Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (e.g., sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (e.g., propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (e.g., Tween®), wetting agents (e.g., sodium lauryl sulfate), colorants, flavorings, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.

[0051] The route of administration of the compound or pharmaceutical composition of the present invention is not particularly limited, and typical routes of administration include (but are not limited to) oral and parenteral (intravenous, intramuscular, or subcutaneous).

[0052] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with (a) a filler or compatibilizer, such as starch, lactose, sucrose, glucose, mannitol, and silicic acid; (b) a binder, such as hydroxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic; (c) a humectant, such as glycerin; or (d) agar, calcium carbonate, potato starch. It is mixed with ingredients such as disintegrating agents such as potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate, (e) retarders such as paraffin, (f) absorption accelerators such as quaternary amine compounds, (g) wetting agents such as cetyl alcohol and glyceryl monostearate, (h) adsorbents such as kaolin, and (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets, and pills, the dosage form may also contain buffering agents.

[0053] Solid dosage forms such as tablets, sugar pills, capsules, pills, and granules can be prepared with coatings and shell materials, such as enteric coatings and other materials known in the art. They can contain opacifying agents, and the release of the active compound or compounds of such compositions can be delayed in a specific part of the digestive tract. Examples of embedding materials that can be used include polymeric substances and waxes. If necessary, the active compound can be formed into microcapsules with one or more of the above-mentioned excipients.

[0054] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, or tinctures. In addition to the active compound, the liquid dosage form can contain an inert diluent conventionally used in the art, such as water or other solvents, and solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, and sesame oil, or mixtures of these substances.

[0055] Besides these inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening agents, flavoring agents, and perfuming agents. In addition to the active compound, suspensions may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and dehydrated sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar-agar, or mixtures of these substances.

[0056] Compositions for parenteral injection can include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.

[0057] The compounds of the present invention can be administered alone or in combination with other pharmaceutically acceptable compounds (eg, other anti-cancer agents). When administered in combination, the pharmaceutical composition further comprises one or more (two, three, four, or more) other pharmaceutically acceptable compounds, which may be used simultaneously, separately, or sequentially with the compounds of the present invention to prevent and / or treat diseases associated with PD-1 / PD-L1 interaction.

[0058] When a pharmaceutical composition is used, a safe and prevalent amount of the compound of the present invention is administered to a mammal (e.g., a human) in need of treatment, and the dosage at the time of administration is the considered effective dose, and for a person weighing 60 kg, the daily dose is usually 1 to 2000 mg, preferably 20 to 500 mg. Of course, the specific dosage must also take into account factors such as the route of administration and the patient's health condition, all of which are within the skill of a skilled physician.

[0059] The main advantages of the present invention are: (1) The compounds of the present invention have high regulatory activity against PD-1 / PD-L1 interaction, strong binding ability to PD-L1 protein, and the ability to relieve IFNγ inhibition by PD-L1. (2) The compounds of the present invention have superior solubility and very low toxicity to normal cells, and therefore can be applied to therapeutic subjects within a wider dose range. (3) Compared with the compounds of the prior art, the compounds of the present invention have better solubility, and therefore have good drug discovery potential; compared with the existing compounds, the compounds of the present invention show good bioavailability in in vivo experiments; and further, compared with the existing compounds, the compounds of the present invention can be easily prepared into pharmaceutically acceptable salts, which facilitates the further formation of formulations. (4) In vivo pharmacodynamic studies show that the compounds of the present invention can significantly inhibit the growth of subcutaneous tumors, regardless of tumor volume or weight, and significantly increase the number of lymphocytes in the blood and spleen of mice.

[0060] Hereinafter, the present invention will be further described in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and do not limit the scope of the present invention. In the following examples, experimental methods without specific conditions are usually in accordance with conventional conditions or conditions suggested by manufacturers. Unless otherwise specified, percentages and parts are calculated by weight percentages and parts by weight. Experimental materials and reagents used in the following examples are available from commercial channels unless otherwise specified.

[0061] Common materials and test methods: A description of the equipment and materials referred to in the examples follows. 1 H NMR spectra are analyzed by a Bruker AV-400 (400 MHz) NMR instrument. Chemical shifts are recorded using tetramethylsilane as an internal standard and are expressed in ppm (CDCl3: δ 7.26 ppm). The recorded data information is as follows: chemical shifts and their splitting and coupling constants (s: singlet, d: doublet, t: triplet, q: quartet, br: broad peak, m: multiplet).

[0062] Mass spectrometry data were analyzed using a Finnigan LCQ Advantage liquid mass spectrometer, unless otherwise specified. All reactions were performed under anhydrous, oxygen-free conditions under the protection of dry argon gas. Solid metal-organic compounds were stored in a dry oven under the protection of argon gas. Tetrahydrofuran and ethyl ether are obtained by distillation, adding sodium metal pre-benzophenone during the distillation. Dichloromethane, pentane and hexane are treated with calcium hydride.

[0063] The special raw materials and intermediates mentioned in this invention are processed and provided by Tianjin Changsen Pharmaceutical Co., Ltd., etc., and all other chemical reagents are purchased from reagent suppliers such as Shanghai Chemical Reagent Company, Aldrich Company, Acros Company, etc. If the intermediates or products required for the reaction during synthesis are not sufficient for the next step, the synthesis will be repeated several times until a sufficient amount is reached. Materials and reagents referred to in this invention may be purchased commercially or by order unless otherwise specified.

[0064] The compounds of the present invention may contain one or more asymmetric centers, and therefore the series of compounds may be in the form of racemates or single enantiomers. The compounds prepared according to the present invention are heterocyclic compounds with purity greater than 95%, and the structure of each final product can be characterized by MS and / or hydrogen nuclear magnetic resonance (NMR). 1 The synthesis of various compounds and intermediates of the present invention is described below by way of examples.

[0065] Example 1. Synthesis of Compound 001 Phase 1-1: [ka] Raw material 1-1 (100 g, 1.0 eq) and sodium hydroxide (27 g, 1.0 eq) were added to water (500 ml) and methanol (2000 ml). The mixture became slightly cloudy and brown. The mixture was cooled to approximately 25°C in an internal tank, and NIS (151 g, 1.0 eq) was added in one portion. The mixture was then allowed to warm naturally and react. The solid increased in volume, then gradually dissolved until it became dark brown and transparent. The reaction was continued for 2 hours, and the reaction mixture was monitored by spot plate and LCMS. 1000 ml of water was added, followed by 2 M hydrochloric acid (400 ml) to make the mixture slightly acidic. The mixture was filtered and rinsed twice with MTBE to obtain 161 g of solid, a yield of 87%. MS-APCI: 275 [M+H] + .

[0066] Phase 1-2: [ka] DMF (1000 ml, 2 BV) was added to a reaction flask, protected with nitrogen gas, and starting material 1-2 (500 g, 1.0 eq) and cuprous cyanide (172 g, 1.05 eq) were added. The mixture was purged with nitrogen gas and heated to 115°C. The reaction was continued for 6 hours, monitored by LCMS, and workup was performed. The mixture was diluted with THF, filtered, and the filtrate was concentrated. The pH was adjusted to 8-9 with aqueous sodium hydroxide (1.1 eq, 6 BV) at room temperature, filtered, and the filtrate was adjusted to 7 with 2M sulfuric acid. Ferrous sulfate and activated carbon were added, stirred at room temperature for 1 hour, filtered, and the filtrate was adjusted to 2-3 with 2M sulfuric acid (400 ml). The solid was filtered, slurried in isopropanol (200 ml) for 30 minutes, filtered, and dried to obtain 211 g of a brown solid. MS-APCI: 174 [M+H] + .

[0067] Stages 1-3: [ka] Dissolve 4.5g of compound 1-3 in 200mL of DCM (500mL single-neck flask), add 6.3g of NIS, and protect with argon gas. Allow to react overnight at room temperature. Monitor the completion of the 1-2 reaction with a TLC spot plate. Add 100ml of 2M HCl to the reaction solution, separate the layers, and dry. Spin dry and purify by column (Hep-DCM 1:1, then DCM) to obtain 6g of pale yellow solid product. MS-APCI: 300 [M+H] + .

[0068] Stages 1-4: [ka] In a 50 mL three-necked flask, 945 mg of compound 1-4, 636 mg of compound 1-5, 25 mg of CuI, and 25 mg of Pd(PPh3)2Cl2 were added, protected with argon gas, and 20 mL of DMF and 1.2 mL of DIPEA were added. The mixture was reacted at 55°C for 3 hours. The disappearance of the raw material was monitored by TLC spot plate. The reaction solution was added to 300 mL of ice water, extracted twice with 300 mL of ethyl acetate, washed once with 2 M NaOH, dried, and spin-dried. Purification was carried out by column chromatography (DCM-MeOH 10:1) to obtain 120 mg of a pale yellow solid. MS-APCI: 364 [M+H] + .

[0069] Stages 1-5: [ka] 215 mg of compound 1-6, 248 mg of azetidine-3-carboxylic acid methyl ester hydrochloride, and 125 mg of Na(CN)BH3 were dissolved in 10 mL of THF, protected with argon gas, and 167 mg of triethylamine was added. The mixture was reacted at 70 °C for 24 hours. The reaction mixture was added to 100 mL of ice water, extracted twice with 100 mL of EA, and dried. Purification was carried out by column chromatography (DCM-MeOH 100, 50:1, 10:1, 5:1) to obtain 53 mg of pale yellow solid 1-7. MS-APCI: 463 [M+H] + .

[0070] Stages 1-6: [ka] 53 mg of raw material 1-7 was dissolved in 5 mL of MeOH, 2 mL of 2 M NaOH was added, and the mixture was reacted at 26°C for 5 hours. The reaction mixture was spin-dried at 40°C, and 50 mL of water was added to the residual solid. The pH value was adjusted to 7 with 2 M HCl. The solid was filtered, washed with water, washed with THF, dried, and further purified to obtain 5 mg of a yellow solid. MS-APCI: 449 [M+H] + .

[0071] The synthesis method for compound 001 is applied to synthesize the compounds in the following table. [ka] [ka] [ka] [ka] [ka]

[0072] Example 2. Synthesis of Compound 026 Stage 2-1: [ka] Raw material 1-3 (110 g, 1.0 eq) was taken and added to acetic acid (660 ml, 6 BV), causing turbidity. The temperature was raised to 40 ° C in the internal bath, and fuming nitric acid (84 g, 2.1 eq) was slowly added dropwise, causing turbidity. The reaction was then maintained at the same temperature for about 1 hour. LCMS showed that 3.5% of the raw material remained. Workup: Cooled to 10 ° C, stirred for 30 minutes, filtered, rinsed with HEP, and dried to obtain 117 g of solid, yield: 84%, purity: 88%. 8% of the raw material was slurried in THF (600 ml) at 50 ° C for 1 hour, and filtered at room temperature to obtain 106 g of solid, yield: 76%. MS-APCI: 219 [M+H] + .

[0073] Stage 2-2: [ka] Raw material 2-4 (20 g, 1.0 eq) and TFA (12 g, 1.1 eq) were added to THF (400 ml, 20 BV). The mixture became cloudy. 5% platinum on carbon (10-20%) was added, and the mixture was purged with hydrogen gas. The reaction was carried out at room temperature and monitored by LCMS (the reaction rate is affected by many factors). After workup, the mixture was filtered, rinsed with 3BV THF, and used directly in the next step. MS-APCI: 189 [M+H] + .

[0074] Stage 2-3: [ka] 2.02 g of compound 2-3 was dissolved in 50 mL of DMAC, 1.98 g of 2-4 was added, and the mixture was reacted under argon gas at room temperature for 3 hours. 3 g of DDQ was added and the mixture was reacted overnight at room temperature. The reaction mixture was poured into 150 mL of water, extracted twice with DCM (100 mL), and dried. The mixture was spin-dried and purified by column chromatography (DCM-MeOH 100, 50:1, 30:1, 20:1, 10:1, 5:1) to obtain 100 mg of a pale yellow solid product. MS-APCI: 387 [M+H] + .

[0075] Stages 2-4: [ka] Intermediate 2-7 (20.7 g, 3.3 eq) was dissolved in THF (143 ml, 10 V / W), and Intermediate 2-8 (14.3 g, 1.0 eq) was added. NaBH3CN (5.0 eq, 11.6 g) was added, and the mixture was purged with nitrogen. The mixture was stirred overnight in an oil bath at 70 °C. LC-MS showed that approximately 15% of 2-7 remained, so the reaction was stopped, cooled to room temperature, and combined with another 1 g batch of the reaction. Water was added, and the mixture was extracted twice with EA. The organic phases were combined, washed with brine, dried, and concentrated. The samples were mixed and passed through a column. Using 2% MeOH in DCM, 17.2 g of product was obtained, and 5.0 g of an off-white solid was obtained at the cross point. Slurry with 100 mL and 20 mL of 1:1 DCM:Hep, stir at room temperature for 10 minutes, filter, rinse with Hep, collect the filter cakes, and dry to give 10.3 g and 1.0 g, respectively. LCMS showed no obvious impurities. Combined, they gave 11.1 g of an off-white solid, HPLC 97.9%, yield 51.8%. Chiral separation gave 4.98 g of Peak 1 and 5.12 g of Peak 2.

[0076] Stages 2-5: [ka] t-Butyl ester 2-9 (1 g, 1.0 eq) was dissolved in TFA (10 v / w) and stirred at room temperature for 1 h. The reaction was confirmed complete by LCMS and directly concentrated to give a yellow-brown oil. Water (10 v / w) was added to the concentrated residue to precipitate a viscous semi-oily semi-solid. The pH was adjusted to 6-7 with saturated NaHCO3 solution, resulting in a large amount of viscous semi-oily and semi-solid material condensing into a mass (1). After coarse filtration once, the filter cake (or paste) was collected, water (20 v / w) was added, and the mixture was sonicated for 5-10 min. The viscous material gradually solidified and partially dispersed. The mixture was stirred at room temperature for 2 h, essentially dispersing, filtered, washed with water, and the filter cake was collected and dried to give 500 mg of product. MS-APCI: 486 [M+H]. + .

[0077] Stages 2-6: [ka] The borate ester starting material 2-11 (commercial, 37 mg), 2-10 (100 mg), potassium phosphate (88 mg), and RuPhos-Pd-G3 (5 mg) were sequentially added to a single-neck flask containing 1,4-dioxane / HO (4:1, 5 mL), protected with nitrogen gas, and stirred in an oil bath at 90 °C for 1 h. The reaction completion was monitored by LC-MS. After completion of the reaction, the mixture was filtered, the solvent was spin-dried, and the product was purified by prep-HPLC to obtain 10 mg of compound 026 (white solid), ESI (APCI): 542 [M+H]. + . 1 H NMR(400MHz,DMSO-d6)δ12.94(s,1H),10.34(s,1H),8.47(s,1H),8.08(dd,J=6.9,2.6Hz,1H),7.77-7.39(m,2H),7.1 0-6.64(m,3H),5.12(s,1H),4.28(s,4H),3.67-3.4(m,3H),3.24-3.15(m,3H),2.37-2.10(m,2H),2.00-1.93(m,1H).

[0078] The synthesis method for compound 002 is applied to synthesize the compounds in the following table. [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka]

[0079] Example 3. Synthesis of Compound 025 Phase 3-1: [ka] Compound 3-1 (1125 mg, 2.32 mmol), cyclopropylsulfonamide (310 mg, 2.56 mmol), DMAP (567 mg, 4.64 mmol), and EDCI (889 mg, 4.64 mmol) were sequentially added to a single-neck flask containing DCM (15 mL) and stirred at room temperature for 1 hour. The reaction was monitored by TLC (ultraviolet light is relatively weak, and the spot plate was washed with 0.5 M dilute hydrochloric acid). After completion of the reaction, the solid was washed with 0.5 M dilute hydrochloric acid, brine, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain 548 mg of a white solid. ESI (APCI): 589 [MH]-.

[0080] Phase 3-2: [ka] Compound borate ester starting material 2-11 (commercial, 28 mg), 2-10 (90 mg), potassium phosphate (88 mg), and XantPhos-PdCl (13 mg) were sequentially added to a single-neck flask containing 1,4-dioxane / HO (4:1, 5 mL), protected with nitrogen gas, and stirred in an oil bath at 90 °C for 2 h. The reaction was monitored by LC-MS. After completion of the reaction, the mixture was filtered, the solvent was spin-dried, and the product was purified by prep-HPLC to obtain 10 mg of compound 025 (white solid), ESI (APCI): 645 [M+H]. + . 1H NMR(400MHz,DMSO-d6)δ 8.50(s,1H),8.11(dd,J=6.8,2.6Hz,1H),7.72-7.61(m,2H),6.99(dd,J=5.2,3.1Hz,2H),6.94(dd,J=8.3,2.1Hz,1H),5.17(d,J=7.0Hz,1H) ,4.31(s,4H),3.49(d,J=8.2Hz,2H),3.32(s,2H),3.24(ddd,J=17.2,8.6,3.1Hz,2H),2.96(dq,J=12.8,6.6,5.9Hz,2H),2.69-2.54(m,2H).

change

change

change

[0081] experiment in biology Example A: Determination of PD-1 / PD-L1 homogeneous time-resolved photon (HTRF) binding The assay was performed in a standard black 384-well polystyrene plate with a final volume of 20 μL. The inhibitor was first serially diluted with DMSO and then added to the wells of the plate, followed by the addition of other reaction components. The final concentration of DMSO during the assay was 1%. The assay was performed at 25°C in PBS buffer (pH 7.4) containing 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a C-terminal His tag was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with a C-terminal Fc tag was also purchased from AcroBiosystems (PD1-H5257). After diluting the PD-L1 and PD-1 proteins with assay buffer, 0.1 μL of the solution was extracted and added to the wells of the plate. The plate was centrifuged, and the proteins were pre-incubated with the inhibitors for 40 minutes. After incubation, 0.1 μl of HTRF detection buffer containing europium-blocked labeled anti-human IgG (PerkinElmer-AD0212) Fc-specific and anti-His SureLight®-allophycocyanin (APC, PerkinElmer-AD0059H) antibodies was added. After centrifugation, the well plate was incubated at 25°C for 60 minutes. The data (665 nm / 620 nm ratio) was read on a PHERAstar FS plate reader. The final concentrations during the measurement were ~3 nM PD1, 10 nM PD-L1, 1 nM europium-blocked anti-human IgG, and 20 nM anti-His-allophycocyanin. The activity data was fitted using GraphPad Prism 5.0 software to determine the IC values ​​of the inhibitors. 50 Get the value.

[0082] IC of the compounds shown in the examples 50 The value is IC 50 It is expressed as follows: +:≦100nM, ++:100nM~1000nM, +++:>1000nM. Data for the example compounds obtained using the PD-1 / PD-L1 homogeneous time-resolved fluorescence (HTRF) binding assay described in Example A are provided in Table 1. [Table 1]

[0083] All documents mentioned in this application are incorporated by reference in the same manner as if each document were incorporated by reference individually. Furthermore, after reading the above teachings of the present invention, those skilled in the art will be able to make various changes or modifications to the present invention, and these equivalents will also be understood to be within the scope defined by the appended claims of this application.

Claims

1. A compound as shown in formula I below, or an optical isomer, hydrate, solvate, or pharmaceutically acceptable salt thereof: 【Chemical Formula 1】 where: 【Chemistry 2】 is the structure shown below: 【Chemistry 3】 n is 0, 1, 2 or 3; m and p are each independently selected from 0, 1, 2, 3, or 4; R ４ teeth, 【Chemistry 4】 wherein Rb and Rc are each independently H, substituted or unsubstituted C １ -C ８ alkyl groups, or Rb and Rc together with the adjacent N atom form a substituted or unsubstituted 4- to 10-membered heterocyclic group having 1 to 3 heteroatoms selected from N, S and O; 【Chemistry 5】 is C ６ -C １０ an aryl group, or a 4- to 12-membered heteroaryl group having 1 to 4 heteroatoms; a 4- to 12-membered heterocyclic group; ５ -C １２ cycloalkyl groups, 【Chemistry 6】 is selected from the group consisting of a phenylene group or a 5- to 7-membered heteroarylene group having 1 to 4 heteroatoms; R, R １ , R ２ , R ３ and R ５ are each independently H, —CN, a trifluoromethyl group, a sulfonylamino group, a nitro group, a hydroxyl group, a halogen, or —S—R ８ , -S(O)-R ８ , -S(O) ２ -R ８ , substituted or unsubstituted C １ -C １０ alkyl group, substituted or unsubstituted C ２ -C ６ Alkenyl group, substituted or unsubstituted C ２ -C ６ Alkynyl group, substituted or unsubstituted C １ -C ６ Alkoxy groups, substituted or unsubstituted C ３ -C ８ selected from the group consisting of cycloalkyl, oxo, NRdRe; or R １ and R ２ together with the ring atoms to which they are attached form a 5-, 6- or 7-membered carbocyclic ring or a 5-, 6- or 7-membered heterocyclic ring, wherein said heterocyclic ring contains 1, 2 or 3 atoms selected from N, S or O, and said carbocyclic or heterocyclic ring may be an aromatic ring attached to ring B or a non-aromatic ring containing an unsaturated bond; R ８ is H, a hydroxyl group, a substituted or unsubstituted C １ -C １０ alkyl group, substituted or unsubstituted C ２ -C ６ Alkenyl group, substituted or unsubstituted C ２ -C ６ Alkynyl group, substituted or unsubstituted C ３ -C ８ cycloalkyl groups, Rd and Re are each independently H, substituted or unsubstituted C １ -C ６ alkyl groups, Unless otherwise specified, the term "substituted" includes halogen, -CH ２ Cl, -CHCl ２ , -CCl ３ , -CH ２ F, -CHF ２ , -CF ３ , oxo, -CN, hydroxyl group, amino group, C １ -C ６ Alkylamino group, carboxyl group, -NHAc, or C １ -C ６ Alkyl group, C １ -C ６ Alkoxy group, C ６ -C １０ Aryl group, C ３ -C ８ Cycloalkyl groups, halogenated C ６ -C １０ any group selected from the group consisting of an aryl group, a 5- to 10-membered heteroaryl group having 1 to 3 heteroatoms selected from N, S, and O, and a 5- to 10-membered heterocyclic group having 1 to 3 heteroatoms selected from N, S, and O, which is unsubstituted or substituted by Rz, wherein Rz is a halogen, a hydroxyl group, a carboxyl group, a cyano group, a C １ -C ６ Alkoxy group, C １ -C ６ alkylamino groups; A compound as shown in formula I, or an optical isomer, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that in each of the above formulas, any of the heteroatoms is selected from the group consisting of B, P, N, S, and O.

2. The aforementioned 【Chemistry 7】 teeth, 【Chemistry 8】 wherein the bonding position of the ring can be N or C.

2. The compound of claim 1, or an optical isomer, hydrate, solvate, or pharmaceutically acceptable salt thereof.

3. The aforementioned 【Chemistry 9】 teeth, 【Chemistry 10】 and wherein R １ and R ２ are each independently H, halogen, substituted or unsubstituted C １ -C １０ alkyl groups selected from the group consisting of The compound of claim 1.

4. The aforementioned 【Chemistry 11】 is the following group: 【Chemistry 12】 【Chemistry 13】 characterized in that the structure is selected from The compound of claim 1.

5. The aforementioned 【Chemistry 14】 is the following group: 【Chemistry 15】 characterized in that the structure is selected from The compound of claim 1.

6. The compound is the following compound: 【Chemistry 16】 【Chemistry 17】 【Chemistry 18】 【Chemistry 19】 【Chemistry 20】 【Chemical 21】 characterized in that it is selected from 2. The compound of claim 1, or an optical isomer, hydrate, solvate, or pharmaceutically acceptable salt thereof.

7. 10. A process for preparing a compound of formula I according to claim 1, comprising: The compound is a compound of formula I-1, The method comprises the steps of: Synthesis method 1: 【Chemical 22】 The preparation method uses intermediates 1 and 2 as raw materials, and obtains the target product I-1 through Sonogashira coupling reaction catalyzed by a palladium catalyst.

8. 8. The method of claim 7, The preparation method of intermediate 1 is as follows: 【Chemical 23】 (a) Compound 1-1 is used as a raw material, and intermediate 1-2 is formed by coupling reaction under the conditions of a palladium catalyst and a ligand; (b) Using 1-2 as a raw material, condensation reaction with primary and secondary amines under Lewis acid catalysis, and further reduction by adding a suitable reducing agent to form intermediate 1-3, or direct reductive amination reaction in the presence of a reducing agent to form intermediate 1-3; (c) The aforementioned method, wherein 1-3 is used as a raw material and is subjected to a halogenation reaction in the presence of a Lewis acid catalyst to obtain intermediate 1.

9. 10. A process for preparing a compound of formula I according to claim 1, comprising: The compound is a compound of formula I-2, The method comprises the steps of: Synthesis method 2: 【Chemistry 24】 (a) Using compound 3-1 as a raw material, reacting with a nitrating agent to form intermediate 3-2; (b) using 3-2 as a raw material, a reduction reaction is carried out under reducing conditions to form intermediate 3-3; (c) Using 3-3 and 3-4 as raw materials, condensation reaction is carried out under the conditions of a condensing agent, and an appropriate oxidizing agent is added to carry out an oxidation reaction to obtain intermediate 3-5; (d) Using 3-5 and 2-1 as raw materials, they are subjected to a coupling reaction under the conditions of a catalyst and a ligand to form intermediate I-2.

10. 1. A pharmaceutical composition comprising: The pharmaceutical composition, comprising: (1) the compound of claim 1 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof; and (2) a pharmaceutically acceptable carrier.

11. 11. Use of a compound according to claim 1 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to claim 10, The use as described above, characterized in that the use is for preparing a pharmaceutical composition for preventing and / or treating a disease associated with the activity or expression level of PD-1 / PD-L1.

12. A PD-1 / PD-L1 modulator, The PD-1 / PD-L1 modulator, characterized in that the modulator comprises the compound of claim 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Images